Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by BeiGene

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pamiparib

            Therapeutic Area: Oncology Product Name: BGB-290

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 27, 2020

            Details:

            The NDA of pamiparib as a potential treatment for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer was accepted in July 2020. It is supported by clinical results from the pivotal Phase 2 portion of the Phase 1/2 trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABI-H0731

            Therapeutic Area: Infections and Infectious Diseases Product Name: ABI-H0731

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: BeiGene

            Deal Size: $540.0 million Upfront Cash: $40.0 million

            Deal Type: Licensing Agreement July 20, 2020

            Details:

            BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABIH2158, and ABI-H3733 in China

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Denosumab

            Therapeutic Area: Oncology Product Name: Xgeva

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: $2,800.0 million Upfront Cash: Undisclosed

            Deal Type: Investment July 12, 2020

            Details:

            This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Beigene-283,Mirdametinib

            Therapeutic Area: Oncology Product Name: BGB-283

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: SpringWorks Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            BeiGene provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ MEK inhibitor, mirdametinib, in solid tumors harboring mutations in the MAPK pathway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zanubrutinib

            Therapeutic Area: Oncology Product Name: Brukinsa

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            BeiGene's Brukinsa (zanubrutinib) has been accepted for review by regulators in Europe to treat patients with Waldenström’s macroglobulinemia (WM).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zanubrutinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2020

            Details:

            BTK inhibitor BRUKINSA™ (zanubrutinib) has received approval from the China NMPA in 2 indications: chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least one prior therapy, and mantle cell lymphoma who have received at least one prior therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tislelizumab,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            Phase 3 results comparing tislelizumab plus chemotherapy to chemotherapy alone met its primary endpoint.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Surufatinib,Tislelizumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hutchison China MediTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 26, 2020

            Details:

            Under this agreement, Chi-Med and BeiGene each plan to explore development of the combination of surufatinib with tislelizumab or fruquintinib with tislelizumab in different indications and regions. The companies have agreed to provide mutual drug supply and other support.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zanubrutinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Medison Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 21, 2020

            Details:

            Medison will commercialize BeiGene’s BTK inhibitor BRUKINSA™ (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for BRUKINSA for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IgM antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Atreca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 29, 2020

            Details:

            The companies will leverage their combined technology in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19.

            PharmaCompass